Download PDF

1. Company Snapshot

1.a. Company Description

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer.The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer.


In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer.The company has a license agreement with EQRx, Inc.and Genor Biopharma Co. Inc.


for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD.for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses.G1 Therapeutics, Inc.


was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Show Full description

1.b. Last Insights on GTHX

G1 Therapeutics' recent performance was driven by a significant acquisition deal with Pharmacosmos Group, which agreed to acquire all outstanding shares of GTHX stock for $7.15 in cash. Additionally, the company reported a narrower-than-expected Q2 loss and topped revenue estimates, indicating a positive trend in its financial performance. The announcement of inducement grants to new employees and the upcoming financial and corporate update on August 8, 2024, also contributed to the company's recent momentum.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer

Sep -18

Source: globenewswire.com

Card image cap

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Primo Water Corporation – PRMW

Aug -09

Source: globenewswire.com

Card image cap

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders

Aug -09

Source: globenewswire.com

Card image cap

G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates

Aug -08

Source: zacks.com

Card image cap

G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights

Aug -08

Source: globenewswire.com

Card image cap

Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders

Aug -07

Source: prnewswire.com

Card image cap

Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?

Aug -07

Source: investorplace.com

Card image cap

Pharmacosmos Group to Acquire G1 Therapeutics

Aug -07

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.76%)

6. Segments

Novel Small Molecule Therapeutics

Expected Growth: 12%

G1 Therapeutics' novel small molecule therapeutics drive 12% growth, fueled by increasing demand for targeted cancer treatments, advancements in precision medicine, and a strong pipeline of innovative compounds. Additionally, strategic partnerships and collaborations accelerate development, while a growing need for effective therapies in underserved patient populations further propels growth.

License Revenue

Expected Growth: 16%

G1 Therapeutics' 16% license revenue growth is driven by increasing adoption of its CDK4/6 inhibitor, trilaciclib, in breast cancer treatment. Strong partnerships with pharmaceutical companies, such as GSK and Simcere, have expanded its global reach. Additionally, the company's growing pipeline of oncology and non-oncology products is expected to contribute to future revenue growth.

7. Detailed Products

Trilaciclib

A CDK4/6 inhibitor for the treatment of patients with metastatic triple-negative breast cancer

Lerociclib

An oral, selective CDK4/6 inhibitor for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) breast cancer

G1T38

An oral, selective CDK4/6 inhibitor for the treatment of patients with myeloid malignancies

8. G1 Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

G1 Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and other diseases.

Bargaining Power Of Customers

G1 Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power among patients and healthcare providers.

Bargaining Power Of Suppliers

G1 Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services.

Threat Of New Entrants

G1 Therapeutics, Inc. has a high threat of new entrants due to the growing demand for cancer therapies and the presence of emerging biotech companies.

Intensity Of Rivalry

G1 Therapeutics, Inc. operates in a highly competitive industry with intense rivalry among established players and emerging companies.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 59.89%
Debt Cost 12.50%
Equity Weight 40.11%
Equity Cost 12.50%
WACC 12.50%
Leverage 149.30%

11. Quality Control: G1 Therapeutics, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
BioCryst Pharmaceuticals

A-Score: 4.4/10

Value: 5.0

Growth: 7.2

Quality: 5.1

Yield: 0.0

Momentum: 5.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Ocular Therapeutix

A-Score: 4.0/10

Value: 6.2

Growth: 5.0

Quality: 4.3

Yield: 0.0

Momentum: 6.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Poseida Therapeutics

A-Score: 3.8/10

Value: 4.2

Growth: 4.6

Quality: 4.1

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
G1 Therapeutics

A-Score: 3.7/10

Value: 6.0

Growth: 6.4

Quality: 4.2

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Immunome

A-Score: 3.6/10

Value: 6.4

Growth: 5.1

Quality: 4.7

Yield: 0.0

Momentum: 4.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Praxis Precision Medicines

A-Score: 3.5/10

Value: 6.0

Growth: 7.9

Quality: 4.7

Yield: 0.0

Momentum: 2.5

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

7.16$

Current Price

7.16$

Potential

-0.00%

Expected Cash-Flows